31 May 2018 - - Basel, Switzerland-based immunotherapy company Nouscom has appointed Adrian Woolfson M.D., Ph.D. as chief medical officer, the company said.
Woolfson will play a key role in leading the company's clinical development of its neoantigen off-the-shelf vaccine targeting tumors associated with microsatellite instability, as well as the personalized neoantigen vaccines and oncolytic virus programs.
He brings over a decade of experience in leading clinical trials in oncology and hematology in the pharmaceutical industry, previously having served as global clinical leads for Pfizer and Bristol-Myers Squibb.
Woolfson's clinical and post-graduate medical training was at Balliol College, Oxford, UK and Addenbrooke's Hospital Cambridge, UK. His Ph.D. and post-doctoral molecular immunology fellowship were supervised by Nobel Prize winner César Milstein.
Privately-held Nouscom, based in Switzerland and Rome, is developing genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer.